|
WO2021066751A1
|
|
Antigen specific binding domains and antibody molecules
|
|
WO2020197502A1
|
|
Treatment employing anti-il-13r antibody or binding fragment thereof
|
|
WO2020076239A1
|
|
Malonate salt of varlitinib
|
|
US2019151326A1
|
|
Cancer therapy
|
|
WO2019083456A1
|
|
Varlitinib for use in treating cancer to normalise angiogenesis in a cancer mass
|
|
WO2019083457A1
|
|
Varlitinib for use in treating cancer in a patient identified as having a beta-catenin pathway mutation
|
|
WO2019083455A1
|
|
Varlitinib for use in treating cancer in a patient identified as having activated her1, her2 and/or her3 receptor cancerous cells
|
|
WO2019083458A1
|
|
Varlitinib for use in treating cancer to reduce hypoxia
|
|
US2019117655A1
|
|
Treatment of Biliary Duct Cancer
|
|
CN110785434A
|
|
Methods of treatment using IL-13R antibodies
|
|
WO2019004943A1
|
|
Method of treatment using il-13r antibody
|
|
WO2018222135A1
|
|
Cancer therapy
|
|
WO2018222134A1
|
|
Cancer therapy
|
|
TW201834649A
|
|
Cancer therapy
|
|
WO2018136009A1
|
|
Combination therapy
|
|
WO2018136010A1
|
|
Combination therapy
|
|
JP2018150292A
|
|
Cancer treatment
|
|
TW201904570A
|
|
Method of treating liver cancer
|
|
EP3445366A1
|
|
Method of treating liver cancer
|
|
GB201703453D0
|
|
Therapy
|
